GlassScriptPhysician profile
Hung T Pham
NPI 1033650023
$10,998.36
in general payments reported to CMS, 2019-2025
34 companies · $3,147 in 2025
The $3,147 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $322 · 2021: $1,513 · 2022: $243 · 2023: $2,006 · 2024: $3,338 · 2025: $3,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,470 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,470.46 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,589.27 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,572.49 | 2021-2025 | |
| Novo Nordisk INC | $1,084.30 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $662.57 | 2021-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $561.15 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $548.12 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Janssen Pharmaceuticals, INC | $524.43 | 2021-2024 | Xarelto |
| Pfizer INC. | $476.12 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $447.00 | 2021-2025 | |
| Amgen INC. | $418.71 | 2023-2025 | Repatha, Otezla, Repatha |
| Esperion Therapeutics, INC. | $407.04 | 2021-2025 | Nexletol |
| Daiichi Sankyo INC. | $347.44 | 2019-2021 | |
| Astellas Pharma US INC | $312.67 | 2021-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $291.32 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $275.83 | 2024-2025 | Rexulti |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $217.76 | 2023-2025 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $182.70 | 2023-2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $161.94 | 2025 | The Cologuard Plus Collection Kit |
| Ironwood Pharmaceuticals, INC | $149.01 | 2023-2025 | Linzess |
| Merck Sharp & Dohme LLC | $87.80 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Teva Pharmaceuticals USA, INC. | $87.49 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $82.59 | 2023-2024 | Quviviq |
| Ardelyx, INC. | $79.10 | 2025 | Ibsrela |
| Dexcom, INC. | $61.42 | 2023-2024 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $58.35 | 2023-2024 | |
| Insulet Corporation | $49.04 | 2025 | Omnipod |
| Kowa Pharmaceuticals America, INC. | $48.87 | 2025 | Zoryve |
| Verona Pharma, INC. | $43.37 | 2025 | Ohtuvayre |
| E.R. Squibb & Sons, L.L.C. | $36.96 | 2021-2024 | Camzyos |
| Axsome Therapeutics, INC. | $33.42 | 2025 | Auvelity |
| Azurity Pharmaceuticals, INC. | $31.14 | 2023 | Edarbi |
| Lundbeck LLC | $26.94 | 2025 | Rexulti |
| Abbott Laboratories | $24.57 | 2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hung Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.